Tags

Type your tag names separated by a space and hit enter

RETRACTED ARTICLE

Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD.
Chest. 2005 Dec; 128(6):3817-27.Chest

Abstract

BACKGROUND

COPD, the fifth-leading cause of death worldwide, is characterized by chronic inflammation. However, no available agent can effectively cure this inflammation. A dietary supplement containing omega-3 polyunsaturated fatty acids (PUFAs) has anti-inflammatory effects. In this study, we hypothesized that nutritional support with omega-3 PUFA-rich diets may be useful for treating COPD, and we compared the clinical features and inflammatory mediator levels between the COPD patients who received an omega-3 PUFA-rich supplement and those who received a nonrich supplement.

METHODS

Sixty-four COPD patients received 400 kilocalories per day of an omega-3 PUFA-rich supplement (n-3 group) or an omega-3 PUFA-nonrich supplement (n-6 group) for 2 years. We prospectively investigated the clinical features of these patients and measured the levels of inflammatory mediators.

RESULTS

In 6-min walk testing, the dyspnea Borg scale and decrease of arterial oxygen saturation measured by pulse oximetry significantly improved in the n-3 group. Leukotriene B4 levels in serum and sputum and tumor necrosis factor-alpha and interleukin-8 levels in sputum decreased significantly in the n-3 group, while there was no significant change in the n-6 group. Two patients in the n-3 group and three patients in the n-6 group had mild diarrhea, and three patients in the n-3 group and three patients in the n-6 group had nausea; however, their symptoms were controllable and they improved with treatment. With multiple regression analysis, it was proved that the omega-3 PUFA-rich diet significantly contributed to the change in cytokine levels in this study.

CONCLUSION

We suggest nutritional support with an omega-3 PUFA-rich diet as a safe and practical method for treating COPD.

Authors+Show Affiliations

Division of Respiratory Medicine, Respiratory and Stress Care Center, Kagoshima University Hospital, Sakuragaoka 8-35-1, Kagoshima 890-8520, Japan. vega@xa2.so-net.ne.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Retracted Publication

Language

eng

PubMed ID

16354850

Citation

Matsuyama, Wataru, et al. "Effects of Omega-3 Polyunsaturated Fatty Acids On Inflammatory Markers in COPD." Chest, vol. 128, no. 6, 2005, pp. 3817-27.
Matsuyama W, Mitsuyama H, Watanabe M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest. 2005;128(6):3817-27.
Matsuyama, W., Mitsuyama, H., Watanabe, M., Oonakahara, K., Higashimoto, I., Osame, M., & Arimura, K. (2005). Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest, 128(6), 3817-27.
Matsuyama W, et al. Effects of Omega-3 Polyunsaturated Fatty Acids On Inflammatory Markers in COPD. Chest. 2005;128(6):3817-27. PubMed PMID: 16354850.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. AU - Matsuyama,Wataru, AU - Mitsuyama,Hideo, AU - Watanabe,Masaki, AU - Oonakahara,Ken-ichi, AU - Higashimoto,Ikkou, AU - Osame,Mitsuhiro, AU - Arimura,Kimiyoshi, PY - 2005/12/16/pubmed PY - 2006/1/18/medline PY - 2005/12/16/entrez SP - 3817 EP - 27 JF - Chest JO - Chest VL - 128 IS - 6 N2 - BACKGROUND: COPD, the fifth-leading cause of death worldwide, is characterized by chronic inflammation. However, no available agent can effectively cure this inflammation. A dietary supplement containing omega-3 polyunsaturated fatty acids (PUFAs) has anti-inflammatory effects. In this study, we hypothesized that nutritional support with omega-3 PUFA-rich diets may be useful for treating COPD, and we compared the clinical features and inflammatory mediator levels between the COPD patients who received an omega-3 PUFA-rich supplement and those who received a nonrich supplement. METHODS: Sixty-four COPD patients received 400 kilocalories per day of an omega-3 PUFA-rich supplement (n-3 group) or an omega-3 PUFA-nonrich supplement (n-6 group) for 2 years. We prospectively investigated the clinical features of these patients and measured the levels of inflammatory mediators. RESULTS: In 6-min walk testing, the dyspnea Borg scale and decrease of arterial oxygen saturation measured by pulse oximetry significantly improved in the n-3 group. Leukotriene B4 levels in serum and sputum and tumor necrosis factor-alpha and interleukin-8 levels in sputum decreased significantly in the n-3 group, while there was no significant change in the n-6 group. Two patients in the n-3 group and three patients in the n-6 group had mild diarrhea, and three patients in the n-3 group and three patients in the n-6 group had nausea; however, their symptoms were controllable and they improved with treatment. With multiple regression analysis, it was proved that the omega-3 PUFA-rich diet significantly contributed to the change in cytokine levels in this study. CONCLUSION: We suggest nutritional support with an omega-3 PUFA-rich diet as a safe and practical method for treating COPD. SN - 0012-3692 UR - https://www.unboundmedicine.com/medline/citation/16354850/Effects_of_omega_3_polyunsaturated_fatty_acids_on_inflammatory_markers_in_COPD_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(15)49623-0 DB - PRIME DP - Unbound Medicine ER -